Table Of Contents
1 Introduction 30
1.1 Objectives Of The Study 30
1.2 Market Definition 30
1.3 Overview Of North America Wound Care Biologics Market 30
1.4 Currency And Pricing 31
1.5 Limitation 31
1.6 Markets Covered 32
2 Market Segmentation 34
2.1 Markets Covered 34
2.2 Geographic Scope 35
2.3 Years Considered For The Study 36
2.4 Currency And Pricing 36
2.5 Research Methodology 37
2.6 Primary Interviews With Key Opinion Leaders 40
2.1 Dbmr Market Position Grid 41
2.2 Dbmr Market Challenge Matrix 42
2.3 Secondary Sources 43
2.4 Assumptions 43
3 Market Overview 44
3.1 Drivers 46
3.1.1 Increasing Cases Of Diabetic Foot Ulcers 46
3.1.2 Increasing Incidences Of Burn Cases 46
3.1.3 Rising Number Of Geriatric Population 47
3.1.4 Innovation In Wound Care Biologics 48
3.1.5 New Product Launches 50
3.2 Restrains 50
3.2.1 High Cost Of Wound Treatment And Wound Care Biologics 50
3.2.2 Risk Of Skin Substitue Failure 51
3.3 Opportunities 52
3.3.1 3D Skin Printing 52
3.3.2 Awareness Programs 53
3.4 Challenges 54
3.4.1 Lack Of Wound Management Services 54
4 Executive Summary 55
5 Premium Insights 58
6 North America Wound Care Biologics Market, By Product Type 63
6.1 Overview 64
6.2 Synthetic Skin Grafts 66
6.3 Growth Factors 67
6.3.1 Platelet Derived Growth Factor (Pdgf) 70
6.3.2 Platelet Rich Plasma (Prp) 70
6.3.3 Epidermal Growth Factors (Egf) 70
6.3.4 Basic Fibroblast Growth Factors (Bfgf) 71
6.3.5 Granulocyte Colony Stimulating Factor (G-Csf) 71
6.3.6 Talactoferrin Alfa 71
6.3.7 Thrombin Peptide 72
6.3.8 Keratinocy Growth Factor (Kgf) 72
6.4 Allografts 73
6.5 Xenografts 74
7 North America Wound Care Biologics Market, By Wound Type 76
7.1 Overview 77
7.2 Wounds 78
7.2.1 Surgical Wound 80
7.2.1.1 Skin Surgery 81
7.2.1.1.1 Wound Closure 82
7.2.1.1.2 Skin Biopsy 82
7.2.1.1.3 Skin Flap 82
7.2.1.1.4 Skin Graft 82
7.2.1.1.5 Others 82
7.2.1.2 Cosmetic Procedure 83
7.2.1.2.1 Brest Enhancement 84
7.2.1.2.2 Facial Contouring 85
7.2.1.2.3 Facial Rejuvenation; 85
7.2.1.2.4 Body Contouring 85
7.2.1.2.5 Skin Rejuvenation 85
7.2.1.2.6 Others 86
7.2.1.3 Gynecologic Procedures 86
7.2.1.3.1 Pubovaginalis Sling 86
7.2.1.3.2 Pelvic Floor Reconstruction 87
7.2.1.3.3 Rectocele Repair Surgery 87
7.2.1.3.4 Others 87
7.2.1.4 Gastrointestinal Procedure 87
7.2.1.4.1 General Gastrointestinal Surgery 88
7.2.1.4.2 Hernia 89
7.2.1.4.3 Others 89
7.2.2 Acute Wounds 90
7.2.3 Chronic Wounds 90
7.2.4 Traumatic Wounds 91
7.3 Burns 91
7.3.1 Ulcers 92
7.3.2 Diabetic Ulcers 94
7.3.3 Pressure Ulcer 94
7.3.4 Venous Ulcer 95
7.3.5 Others 95
8 North America Wound Care Biologics Market, By End User 96
8.1 Overview 97
8.2 Hospitals 99
8.3 Wound Care Centers 100
8.4 Ambulatory Surgical Centers 101
8.5 Clinics 103
8.6 Community Healthcare Center 104
9 North America Wound Care Biologics Market; Geography 105
9.1 North America 105
9.1.1 U.S. 116
9.1.2 Canada 123
9.1.3 Mexico 130
10 North America Wound Care Biologics Market, Company Landscape 137
10.1 Company Share Analysis; North America 137
11 Company Profile 138
11.1 Mimedx. 138
11.1.1 Company Overview 138
11.1.2 Revenue Analysis; 138
11.1.3 Company Share Analysis; 139
11.1.4 Product Portfolio 139
11.1.5 Recent Developments 140
11.2 Organogenesis Inc 141
11.2.1 Company Overview 141
11.2.2 Geographic Presence 141
11.2.3 Company Share Analysis; 142
11.2.4 Product Portfolio 142
11.2.5 Recent Developments 143
11.3 Integra Lifesciences 144
11.3.1 Company Overview 144
11.3.2 Revenue Analysis 144
11.3.3 Company Share Analysis; 145
11.3.4 Product Portfolio 145
11.3.5 Recent Developments 146
11.4 Convatec Inc. 147
11.4.1 Company Overview 147
11.4.2 Revenue Analysis 147
11.4.3 Company Share Analysis; 148
11.4.4 Product Portfolio ; 148
11.4.5 Recent Developments 148
11.5 Acell Inc. 149
11.5.1 Company Overview 149
11.5.2 Product Portfolio 149
11.5.3 Recent Developments 150
11.6 Allosource 151
11.6.1 Company Overview 151
11.6.2 Product Portfolio 151
11.6.3 Recent Developments 152
11.7 Alphatec Spine, Inc. ( A Subsidary Of Alphatec Holdings, Inc) 153
11.7.1 Company Overview 153
11.7.2 Product Portfolio 153
11.7.3 Recent Developments 153
11.8 Amnio Technology, Llc 154
11.8.1 Company Overview 154
11.8.2 Product Portfolio 154
11.8.3 Recent Developments 155
11.9 Amniox Medical, Inc. 156
11.9.1 Company Overview 156
11.9.2 Product Portfolio 156
11.9.3 Recent Developments 157
11.10 Anika Therapeutics, Inc. 158
11.10.1 Company Overview 158
11.10.2 Revenue Analysis 158
11.10.3 Product Portfolio 159
11.10.4 Recent Developments 159
11.11 Biohorizons Iph, Inc ( A Subsidary Of Henry Schein, Inc.) 160
11.11.1 Company Overview 160
11.11.2 Geographicpresence 160
11.11.3 Product Portfolio 161
11.11.4 Recent Developments 161
11.12 Kerecis 162
11.12.1 Company Overview 162
11.12.2 Geographical Presence 162
11.12.3 Product Portfolio 163
11.12.4 Recent Developments 163
11.13 Marine Polymer Technologies, Inc 164
11.13.1 Company Overview 164
11.13.2 Product Portfolio 164
11.13.3 Recent Developments 164
11.14 M?lnlycke Health Care Ab 165
11.14.1 Company Overview 165
11.14.2 Revenue Analysis 165
11.14.3 Product Portfolio 166
11.14.4 Recent Developments 166
11.15 Osiris Therapeutics, Inc. 167
11.15.1 Company Overview 167
11.15.2 Revenue Analysis 167
11.15.3 Product Portfolio 168
11.15.4 Recent Developments 168
11.16 Skye Biologics Inc. 169
11.16.1 Company Overview 169
11.16.2 Product Portfolio ; 169
11.16.3 Recent Development; 170
11.17 Smith And Nephew 171
11.17.1 Company Overview 171
11.17.2 Revenue Analysis 171
11.17.3 Product Portfolio 172
11.17.4 Recent Developments 172
11.18 Solsys Medical. 173
11.18.1 Company Overview 173
11.18.2 Product Portfolio 174
11.18.3 Recent Developments 174
11.19 Vericel Corporation. 175
11.19.1 Company Overview 175
11.19.2 1.1.2 Revenue Analysis 175
11.19.3 Product Portfolio 176
11.19.4 Recent Developments 176
11.20 Wright Medical Group N.V 177
11.20.1 Company Overview 177
11.20.2 1.1.2 Revenue Analysis 177
11.20.3 Product Portfolio 178
11.20.4 Recent Developments 179
12 Related Reports 180
?